Market Executive Summary
The global market for Checkpoint Inhibitors for Treating Cancer was estimated to be worth US$ 19640 million in 2024 and is forecast to a readjusted size of US$ 94850 million by 2031 with a CAGR of 25.6% during the forecast period 2025-2031.
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.
This report aims to provide a comprehensive presentation of the global market for Checkpoint Inhibitors for Treating Cancer, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Checkpoint Inhibitors for Treating Cancer by region & country, by Type, and by Application.
The Checkpoint Inhibitors for Treating Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Checkpoint Inhibitors for Treating Cancer.
Global Checkpoint Inhibitors for Treating Cancer Companies Covered
Bristol-Myers Squibb(BMS), Merck, Roche
Global Checkpoint Inhibitors for Treating Cancer Market, by Region
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Checkpoint Inhibitors for Treating Cancer Market, Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Global Checkpoint Inhibitors for Treating Cancer Market, Segment by Application
Melanoma Treatment
Bladder Cancer Treatment
Other
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Checkpoint Inhibitors for Treating Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Checkpoint Inhibitors for Treating Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Checkpoint Inhibitors for Treating Cancer in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Related Report:
Global Cancer Drug based on PARP Inhibitor Market Size, Share, Growth Drivers, Trends, Opportunities, Competitive Analysis, and Demand Forecast To 2030
Global Anticancer Drugs Market Size, Share, Growth Drivers, Trends, Opportunities, Competitive Analysis, and Forecast to 2030
Table of Contents
Table of Contents
1 Market Overview
1.1 Checkpoint Inhibitors for Treating Cancer Product Introduction
1.2 Global Checkpoint Inhibitors for Treating Cancer Market Size Forecast
1.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Value (2020-2031)
1.2.2 Global Checkpoint Inhibitors for Treating Cancer Sales Volume (2020-2031)
1.2.3 Global Checkpoint Inhibitors for Treating Cancer Sales Price (2020-2031)
1.3 Checkpoint Inhibitors for Treating Cancer Market Trends & Drivers
1.3.1 Checkpoint Inhibitors for Treating Cancer Industry Trends
1.3.2 Checkpoint Inhibitors for Treating Cancer Market Drivers & Opportunity
1.3.3 Checkpoint Inhibitors for Treating Cancer Market Challenges
1.3.4 Checkpoint Inhibitors for Treating Cancer Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Checkpoint Inhibitors for Treating Cancer Players Revenue Ranking (2024)
2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Company (2020-2025)
2.3 Global Checkpoint Inhibitors for Treating Cancer Players Sales Volume Ranking (2024)
2.4 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Company Players (2020-2025)
2.5 Global Checkpoint Inhibitors for Treating Cancer Average Price by Company (2020-2025)
2.6 Key Manufacturers Checkpoint Inhibitors for Treating Cancer Manufacturing Base and Headquarters
2.7 Key Manufacturers Checkpoint Inhibitors for Treating Cancer Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Checkpoint Inhibitors for Treating Cancer
2.9 Checkpoint Inhibitors for Treating Cancer Market Competitive Analysis
2.9.1 Checkpoint Inhibitors for Treating Cancer Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Checkpoint Inhibitors for Treating Cancer Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 PD-1 Inhibitors
3.1.2 PD-L1 Inhibitors
3.1.3 CTLA-4 Inhibitors
3.2 Global Checkpoint Inhibitors for Treating Cancer Sales Value by Type
3.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Checkpoint Inhibitors for Treating Cancer Sales Value, by Type (2020-2031)
3.2.3 Global Checkpoint Inhibitors for Treating Cancer Sales Value, by Type (%) (2020-2031)
3.3 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Type
3.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Checkpoint Inhibitors for Treating Cancer Sales Volume, by Type (2020-2031)
3.3.3 Global Checkpoint Inhibitors for Treating Cancer Sales Volume, by Type (%) (2020-2031)
3.4 Global Checkpoint Inhibitors for Treating Cancer Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Melanoma Treatment
4.1.2 Bladder Cancer Treatment
4.1.3 Other
4.2 Global Checkpoint Inhibitors for Treating Cancer Sales Value by Application
4.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Checkpoint Inhibitors for Treating Cancer Sales Value, by Application (2020-2031)
4.2.3 Global Checkpoint Inhibitors for Treating Cancer Sales Value, by Application (%) (2020-2031)
4.3 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Application
4.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Checkpoint Inhibitors for Treating Cancer Sales Volume, by Application (2020-2031)
4.3.3 Global Checkpoint Inhibitors for Treating Cancer Sales Volume, by Application (%) (2020-2031)
4.4 Global Checkpoint Inhibitors for Treating Cancer Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Checkpoint Inhibitors for Treating Cancer Sales Value by Region
5.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Value by Region (2020-2025)
5.1.3 Global Checkpoint Inhibitors for Treating Cancer Sales Value by Region (2026-2031)
5.1.4 Global Checkpoint Inhibitors for Treating Cancer Sales Value by Region (%), (2020-2031)
5.2 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Region
5.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Region (2020-2025)
5.2.3 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Region (2026-2031)
5.2.4 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Region (%), (2020-2031)
5.3 Global Checkpoint Inhibitors for Treating Cancer Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
5.4.2 North America Checkpoint Inhibitors for Treating Cancer Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
5.5.2 Europe Checkpoint Inhibitors for Treating Cancer Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
5.6.2 Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
5.7.2 South America Checkpoint Inhibitors for Treating Cancer Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
5.8.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Checkpoint Inhibitors for Treating Cancer Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Checkpoint Inhibitors for Treating Cancer Sales Value
6.2.1 Key Countries/Regions Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
6.2.2 Key Countries/Regions Checkpoint Inhibitors for Treating Cancer Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
6.3.2 United States Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Checkpoint Inhibitors for Treating Cancer Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
6.4.2 Europe Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Checkpoint Inhibitors for Treating Cancer Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
6.5.2 China Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
6.5.3 China Checkpoint Inhibitors for Treating Cancer Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
6.6.2 Japan Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Checkpoint Inhibitors for Treating Cancer Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
6.7.2 South Korea Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Checkpoint Inhibitors for Treating Cancer Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
6.8.2 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Checkpoint Inhibitors for Treating Cancer Sales Value, 2020-2031
6.9.2 India Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
6.9.3 India Checkpoint Inhibitors for Treating Cancer Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Bristol-Myers Squibb(BMS)
7.1.1 Bristol-Myers Squibb(BMS) Company Information
7.1.2 Bristol-Myers Squibb(BMS) Introduction and Business Overview
7.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product Offerings
7.1.5 Bristol-Myers Squibb(BMS) Recent Development
7.2 Merck
7.2.1 Merck Company Information
7.2.2 Merck Introduction and Business Overview
7.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Merck Checkpoint Inhibitors for Treating Cancer Product Offerings
7.2.5 Merck Recent Development
7.3 Roche
7.3.1 Roche Company Information
7.3.2 Roche Introduction and Business Overview
7.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Roche Checkpoint Inhibitors for Treating Cancer Product Offerings
7.3.5 Roche Recent Development
8 Industry Chain Analysis
8.1 Checkpoint Inhibitors for Treating Cancer Industrial Chain
8.2 Checkpoint Inhibitors for Treating Cancer Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Checkpoint Inhibitors for Treating Cancer Sales Model
8.5.2 Sales Channel
8.5.3 Checkpoint Inhibitors for Treating Cancer Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Figures
Table of Figures
List of Tables
Table 1. Checkpoint Inhibitors for Treating Cancer Market Trends
Table 2. Checkpoint Inhibitors for Treating Cancer Market Drivers & Opportunity
Table 3. Checkpoint Inhibitors for Treating Cancer Market Challenges
Table 4. Checkpoint Inhibitors for Treating Cancer Market Restraints
Table 5. Global Checkpoint Inhibitors for Treating Cancer Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Company (2020-2025)
Table 7. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Company (2020-2025) & (K Units)
Table 8. Global Checkpoint Inhibitors for Treating Cancer Sales Volume Market Share by Company (2020-2025)
Table 9. Global Market Checkpoint Inhibitors for Treating Cancer Price by Company (2020-2025) & (USD/Unit)
Table 10. Key Manufacturers Checkpoint Inhibitors for Treating Cancer Manufacturing Base and Headquarters
Table 11. Key Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Checkpoint Inhibitors for Treating Cancer
Table 13. Global Checkpoint Inhibitors for Treating Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2024)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Type (2020-2025) & (US$ Million)
Table 18. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Type (2026-2031) & (US$ Million)
Table 19. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Type (2020-2025)
Table 20. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Type (2026-2031)
Table 21. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
Table 22. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Type (2020-2025) & (K Units)
Table 23. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Type (2026-2031) & (K Units)
Table 24. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Type (2020-2025)
Table 25. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Type (2026-2031)
Table 26. Global Checkpoint Inhibitors for Treating Cancer Price by Type (2020-2025) & (USD/Unit)
Table 27. Global Checkpoint Inhibitors for Treating Cancer Price by Type (2026-2031) & (USD/Unit)
Table 28. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Application (2020-2025) & (US$ Million)
Table 30. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Application (2026-2031) & (US$ Million)
Table 31. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Application (2020-2025)
Table 32. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Value by Application (2026-2031)
Table 33. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
Table 34. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Application (2020-2025) & (K Units)
Table 35. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Application (2026-2031) & (K Units)
Table 36. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Application (2020-2025)
Table 37. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share in Volume by Application (2026-2031)
Table 38. Global Checkpoint Inhibitors for Treating Cancer Price by Application (2020-2025) & (USD/Unit)
Table 39. Global Checkpoint Inhibitors for Treating Cancer Price by Application (2026-2031) & (USD/Unit)
Table 40. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 41. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Region (2020-2025) & (US$ Million)
Table 42. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Region (2026-2031) & (US$ Million)
Table 43. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Region (2020-2025) & (%)
Table 44. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Region (2026-2031) & (%)
Table 45. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
Table 46. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Region (2020-2025) & (K Units)
Table 47. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Region (2026-2031) & (K Units)
Table 48. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Region (2020-2025) & (%)
Table 49. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Region (2026-2031) & (%)
Table 50. Global Checkpoint Inhibitors for Treating Cancer Average Price by Region (2020-2025) & (USD/Unit)
Table 51. Global Checkpoint Inhibitors for Treating Cancer Average Price by Region (2026-2031) & (USD/Unit)
Table 52. Key Countries/Regions Checkpoint Inhibitors for Treating Cancer Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 53. Key Countries/Regions Checkpoint Inhibitors for Treating Cancer Sales Value, (2020-2025) & (US$ Million)
Table 54. Key Countries/Regions Checkpoint Inhibitors for Treating Cancer Sales Value, (2026-2031) & (US$ Million)
Table 55. Key Countries/Regions Checkpoint Inhibitors for Treating Cancer Sales Volume, (2020-2025) & (K Units)
Table 56. Key Countries/Regions Checkpoint Inhibitors for Treating Cancer Sales Volume, (2026-2031) & (K Units)
Table 57. Bristol-Myers Squibb(BMS) Company Information
Table 58. Bristol-Myers Squibb(BMS) Introduction and Business Overview
Table 59. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product Offerings
Table 61. Bristol-Myers Squibb(BMS) Recent Development
Table 62. Merck Company Information
Table 63. Merck Introduction and Business Overview
Table 64. Merck Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. Merck Checkpoint Inhibitors for Treating Cancer Product Offerings
Table 66. Merck Recent Development
Table 67. Roche Company Information
Table 68. Roche Introduction and Business Overview
Table 69. Roche Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 70. Roche Checkpoint Inhibitors for Treating Cancer Product Offerings
Table 71. Roche Recent Development
Table 72. Key Raw Materials Lists
Table 73. Raw Materials Key Suppliers Lists
Table 74. Checkpoint Inhibitors for Treating Cancer Downstream Customers
Table 75. Checkpoint Inhibitors for Treating Cancer Distributors List
Table 76. Research Programs/Design for This Report
Table 77. Key Data Information from Secondary Sources
Table 78. Key Data Information from Primary Sources
List of Figures
Figure 1. Checkpoint Inhibitors for Treating Cancer Product Picture
Figure 2. Global Checkpoint Inhibitors for Treating Cancer Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Checkpoint Inhibitors for Treating Cancer Sales Value (2020-2031) & (US$ Million)
Figure 4. Global Checkpoint Inhibitors for Treating Cancer Sales Volume (2020-2031) & (K Units)
Figure 5. Global Checkpoint Inhibitors for Treating Cancer Sales Price (2020-2031) & (USD/Unit)
Figure 6. Checkpoint Inhibitors for Treating Cancer Report Years Considered
Figure 7. Global Checkpoint Inhibitors for Treating Cancer Players Revenue Ranking (2024) & (US$ Million)
Figure 8. Global Checkpoint Inhibitors for Treating Cancer Players Sales Volume Ranking (2024) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Checkpoint Inhibitors for Treating Cancer Revenue in 2024
Figure 10. Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 11. PD-1 Inhibitors Picture
Figure 12. PD-L1 Inhibitors Picture
Figure 13. CTLA-4 Inhibitors Picture
Figure 14. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 15. Global Checkpoint Inhibitors for Treating Cancer Sales Value Market Share by Type, 2024 & 2031
Figure 16. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Sales Volume Market Share by Type, 2024 & 2031
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Price by Type (2020-2031) & (USD/Unit)
Figure 19. Product Picture of Melanoma Treatment
Figure 20. Product Picture of Bladder Cancer Treatment
Figure 21. Product Picture of Other
Figure 22. Global Checkpoint Inhibitors for Treating Cancer Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 23. Global Checkpoint Inhibitors for Treating Cancer Sales Value Market Share by Application, 2024 & 2031
Figure 24. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
Figure 25. Global Checkpoint Inhibitors for Treating Cancer Sales Volume Market Share by Application, 2024 & 2031
Figure 26. Global Checkpoint Inhibitors for Treating Cancer Price by Application (2020-2031) & (USD/Unit)
Figure 27. North America Checkpoint Inhibitors for Treating Cancer Sales Value (2020-2031) & (US$ Million)
Figure 28. North America Checkpoint Inhibitors for Treating Cancer Sales Value by Country (%), 2024 VS 2031
Figure 29. Europe Checkpoint Inhibitors for Treating Cancer Sales Value, (2020-2031) & (US$ Million)
Figure 30. Europe Checkpoint Inhibitors for Treating Cancer Sales Value by Country (%), 2024 VS 2031
Figure 31. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Value, (2020-2031) & (US$ Million)
Figure 32. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Value by Region (%), 2024 VS 2031
Figure 33. South America Checkpoint Inhibitors for Treating Cancer Sales Value, (2020-2031) & (US$ Million)
Figure 34. South America Checkpoint Inhibitors for Treating Cancer Sales Value by Country (%), 2024 VS 2031
Figure 35. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Value, (2020-2031) & (US$ Million)
Figure 36. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Value by Country (%), 2024 VS 2031
Figure 37. Key Countries/Regions Checkpoint Inhibitors for Treating Cancer Sales Value (%), (2020-2031)
Figure 38. Key Countries/Regions Checkpoint Inhibitors for Treating Cancer Sales Volume (%), (2020-2031)
Figure 39. United States Checkpoint Inhibitors for Treating Cancer Sales Value, (2020-2031) & (US$ Million)
Figure 40. United States Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
Figure 41. United States Checkpoint Inhibitors for Treating Cancer Sales Value by Application (%), 2024 VS 2031
Figure 42. Europe Checkpoint Inhibitors for Treating Cancer Sales Value, (2020-2031) & (US$ Million)
Figure 43. Europe Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
Figure 44. Europe Checkpoint Inhibitors for Treating Cancer Sales Value by Application (%), 2024 VS 2031
Figure 45. China Checkpoint Inhibitors for Treating Cancer Sales Value, (2020-2031) & (US$ Million)
Figure 46. China Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
Figure 47. China Checkpoint Inhibitors for Treating Cancer Sales Value by Application (%), 2024 VS 2031
Figure 48. Japan Checkpoint Inhibitors for Treating Cancer Sales Value, (2020-2031) & (US$ Million)
Figure 49. Japan Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
Figure 50. Japan Checkpoint Inhibitors for Treating Cancer Sales Value by Application (%), 2024 VS 2031
Figure 51. South Korea Checkpoint Inhibitors for Treating Cancer Sales Value, (2020-2031) & (US$ Million)
Figure 52. South Korea Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
Figure 53. South Korea Checkpoint Inhibitors for Treating Cancer Sales Value by Application (%), 2024 VS 2031
Figure 54. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Value, (2020-2031) & (US$ Million)
Figure 55. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
Figure 56. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Value by Application (%), 2024 VS 2031
Figure 57. India Checkpoint Inhibitors for Treating Cancer Sales Value, (2020-2031) & (US$ Million)
Figure 58. India Checkpoint Inhibitors for Treating Cancer Sales Value by Type (%), 2024 VS 2031
Figure 59. India Checkpoint Inhibitors for Treating Cancer Sales Value by Application (%), 2024 VS 2031
Figure 60. Checkpoint Inhibitors for Treating Cancer Industrial Chain
Figure 61. Checkpoint Inhibitors for Treating Cancer Manufacturing Cost Structure
Figure 62. Channels of Distribution (Direct Sales, and Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
This report focuses on:
► Intelligent insights to take informed business decisions.
► Qualitative and quantitative analysis of the market.
► Market size and forecasts from 2024 to 2030.
► Opportunities for expansion and in-depth market analysis.
► Segmentation and regional revenue forecasts.
► Analysis of the market share and competitive landscape.
► Strategic recommendations for future growth.
You'll also receive:
► A comprehensive market research report in PDF or PPT formats.
► Access to our analysts to learn more about the report and get answers to your specific business questions.
► The option to customize the report to meet your specific needs, such as adding more countries or regions or developing abusiness case to launch a new product.
Contact us today to learn more and get sample report.
Our Research Reports Look Like This
